The results showed that the overall survival (OS) and disease-free survival (DFS) of ESCC patients with higher MTX2-6 expression were better than those of patients with lower MTX2-6 expression (Figures 1E,F). The gene discussed is MTX2; the disease is esophageal squamous cell carcinoma.